Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 10-Year Outcome of Complete or Infarct Artery-Only Revascularization in STEMI With Multivessel Disease: The DANAMI-3-PRIMULTI Study1 passage
• 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines1 passage
• 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures1 passage
• 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology1 passage
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines1 passage
• Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF1 passage
• Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study1 passage
• Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials1 passage
• Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction1 passage
• Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists1 passage
• Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes1 passage
• Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials1 passage
• Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery1 passage
• Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction1 passage
• Association of IL-8 With Infarct Size and Clinical Outcomes in Patients With STEMI1 passage
• Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program1 passage
• Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT1 passage
• Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week1 passage
• Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome1 passage
• Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT1 passage
• Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial1 passage
• Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation1 passage
• Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction1 passage
• Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology1 passage
• Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction1 passage
• Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial1 passage
• Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease1 passage
• Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure1 passage
• Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction1 passage
• Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure1 passage
• Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials1 passage
• Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study1 passage
• Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis1 passage
• Guiding Therapy by Coronary CT Angiography Improves Outcomes in Patients With Stable Chest Pain1 passage
• Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations1 passage
• Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial1 passage
• Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study1 passage
• Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction1 passage
• Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events1 passage
• Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease1 passage
• Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program1 passage
• Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis1 passage
• Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial1 passage
• Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced1 passage
• Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation1 passage
• Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction Without Shock: The ST-Segment Elevation Myocardial Infarction Door to Unload Randomized Controlled Trial1 passage
• Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl1 passage
• Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial1 passage
• Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization1 passage
• Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction1 passage
• Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)1 passage
• Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants1 passage
• Myocardial Damage in Patients With Deferred Stenting After STEMI: A DANAMI-3-DEFER Substudy1 passage
• N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention1 passage
• Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis1 passage
• Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis1 passage
• Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events1 passage
• Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia1 passage
• Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis1 passage
• Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-06161 passage
• Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization1 passage
• Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome1 passage
• Potent P2Y(12) Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy1 passage
• Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation1 passage
• Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF1 passage
• Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy1 passage
• Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction1 passage
• Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial1 passage
• Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial1 passage
• Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure1 passage
• Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program1 passage
• Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program1 passage
• Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure1 passage
• Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial1 passage
• Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function1 passage
• Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial1 passage
• Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology1 passage
• Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines1 passage
• Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines1 passage
• Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials1 passage
• Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan1 passage
• Thromboprophylaxis in Patients With Fontan Circulation1 passage
• Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy1 passage
• Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease1 passage
• Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance1 passage
• Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease1 passage
• Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology1 passage
• Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease1 passage